Contents

Search

alogliptin (Nesina)

Indications: - diabetes mellitus type 2 - for use in combination with diet & exercise [1] Contraindications: - does not decrease risk of cardiovascular events after acute coronary syndrome [2] Dosage: tablet Adverse effects: - rhinorrhea - upper respiratory tract infection - headache - risk for hypoglycemia is low - may increase risk of may increase the risk of heart failure, particularly in patients with heart disease or kidney disease [3,4] Mechanism of action: - gliptin - lowers hemoglobin A1c 0.3% compared with placebo [2]

Interactions

drug adverse effects of hypoglycemic agents

General

gliptin; dipeptidyl peptidase-4 inhibitor; DPP-4 inhibitor

Database Correlations

PUBCHEM cid=11450633

References

  1. FDA News Release: Jan. 25, 2013 FDA approves three new drug treatments for type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm
  2. White WB et al. for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 Sep 2 PMID: 23992602 http://www.nejm.org/doi/full/10.1056/NEJMoa1305889
  3. Zannad F et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet 2015 Mar 9; PMID: 25765696 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2962225-X/abstract - Standl E and Schnell O. DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet 2015 Mar 9 PMID: 25765695 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2960037-X/abstract
  4. FDA Safety Alert. April 5, 2015 Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication - Risk of Heart Failure. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm

Component-of

alogliptin/metformin (Kazano) alogliptin/pioglitazone (Oseni)